Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo

British Journal of Pharmacology

Volumn 122, Issue 6, 1997, Pages 1061-1066

  Isaji, Masayuki ^a   Miyata, Hiroshi ^a   Ajisawa, Yoshiyuki ^a   Takehana, Yasuo ^b   Yoshimura, Nagahisa ^b  

^a Discov Res R D Kissei P   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Chemotaxis; Microvascular endothelial cells; Proliferation; Tranilast; Tube formation; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; GELATINASE A; GELATINASE B; HEPARIN; LACTATE DEHYDROGENASE; MATRIGEL; TRANILAST; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ANIMALS; ANTHRANILIC ACIDS; CELL DIVISION; CELLS, CULTURED; CHEMOTAXIS; COLLAGENASES; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; GELATINASES; HUMANS; LYMPHOKINES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030844133     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701493     Document Type: Article

References (32)

1. AZUMA, H., BANNO, K. & YOSHIMURA, T. (1976). Pharmacological properties of N-(3′,4′-dimethoxycinnamoyl)anthranilic acid (N-5′), a new anti-atopic agent. Br. J. Pharmacol., 58, 483-488.
2. BATTEGAY, E.J. (1995). Angiogenesis mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med., 73, 333-346.
3. CASTELLOT, J.J., KAMBE, A.M., DOBSON, D.E. & SPIEGELMAN, B.M. (1986). Heparin potentiation of 3T3-adipocyte stimulated angiogenesis: mechanism of action on endothelial cells. J. Cell. Physiol., 127, 323-329.
4. FABUNMI, R.P., BAKER, A.H., MURRAY, E.J., BOOTH, R.F. & NEWBY, A.C. (1996). Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors or metalloproteinase-1, -2 and -3 in rabbit aortic smooth muscle cells. Biochem. J., 315, 335-342.
5. FERRARA, N. & DAVIS-SMYTH, T. (1997). The biology of vascular endothelial growth factor. Endocrinol. Rev., 18, 4-25.
6. FOLKMAN, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med., 1, 27-31.
7. FUKUYAMA, J., ICHIKAWA, K., MIYAZAWA, K., HAMANO, S., SHIBATA, N. & UJIIE, A. (1996). Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits. Japn. J. Pharmacol., 70, 321-327.
8. GARNER, A. (1993). Histopathology of diabetic retinopathy in man. Eye, 7, 250-253.
9. HARALABOPOULOS, G.C., GRANT, D.S., KLEINMAN, H.K., LELKES, P.I., PAPAIOANNOU, S.P. & MARAGOUDAKIS, M.E. (1994). Inhibitors of basement membrane collagen synthesis prevent endothelial cell alignment in matrigel in vitro and angiogenesis in vivo. Lab. Invest., 71, 575-582.
10. HENRY, P.D. (1990). Antiatherogenic effects of calcium-channel blockers: possible mechanisms of action. Cardiovas. Drugs Ther., 4, 1015-1020.
11. HU, D.E. & FAN, T.-P.D. (1995). Suppression of VEGF-induced angiogenesis by the protein tyrosine kinase inhibitor, lavendustin A. Br. J. Pharmacol., 114, 262-268.
12. INGBER, D., FUJITA, T., KISHIMOTO, S., SUDO, K., KANAMARU, T., BREM, H. & FOLKMAN, J. (1990). Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature, 348, 555-557.
13. ISAJI, M., ARUGA, N., NAITO, J. & MIYATA, H. (1994). Inhibition by tranilast of collagen accumulation in hypersensitive granulomatous inflammation in vivo and of morphological changes and functions of fibroblasts in vitro. Life Sci., 55, PL287-P292.
14. ISAJI, M., NAKAJOH, M. & NAITO, J. (1987). Selective inhibition of collagen accumulation by N-(3,4-dimethoxycinnamoyl)anthranilic acid (N-5′) in granulation tissue. Biochem. Pharmacol., 36, 469-474.
15. KATO, K., TAMAI, H., HAYAKAWA, H., YAMAGUCHI, T., KANMATSUSE, K., HAZE, K., AIZAWA, T., SUZUKI, S., TAKASE, S., SUZUKI, T., NISHIKAWA, H., NAKANISHI, S., KATO, O. & NAKASHIMA, M. (1996). Clinical evaluation of tranilast on restenosis after percutaneous transluminal coronary angioplasty (PTCA). A double-blind placebo-controlled comparative study. J. Clin. Ther. Med., 12, 65-85.
16. KILLINGSWORTH, M.C. (1995). Angiogenesis in early choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol., 233, 313-323.
17. KODA, A., NAGAI, H., WATANABE, S., YANAGIHARA, Y. & SAKAMOTO, K. (1976). Inhibition of hypersensitivity reactions by a new drug, N-(3′,4′-dimethoxycinnamoyl)anthranilic acid (N-5′). J. Allergy Clin. Immunol., 57, 396-407.
18. KODA, A., KURASHINA, Y. & NAKAZAWA, M. (1985). The inhibition mechanism of histamine release by N-(3,4-dimethoxycinnamoyl) anthranilic acid. Int. Archs. Allergy Appl. Immun., 77, 244-245.
19. KUBOTA, Y., KLEINMAN, H.K., MARTIN, G.R. & LAWLEY, T.J. (1988). Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J. Cell Biol., 107, 1589-1598.
20. LANE, T.A. & LAMKIN, G.E. (1984). A reassessment of the energy requirements for neutrophil migration: adenosine triphosphate depletion enhances chemotaxis. Blood, 64, 986-993.
21. NORRBY, K. & SORBO, J. (1992). Heparin enhances angiogenesis by a systemic mode of action. Int. J. Exp. Pathol., 73, 147-155.
22. PASSANITI, A., TAYLOR, R.M., PILI, R., GUO, Y., LONG, P.V., HANEY, J.A., PAULY, R.R., GRANT, D.S. & MARTIN, G.R. (1992). A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest., 67, 519-528.
23. POOLE, A.R. (1993). Cartilage in health and disease. In Arthritis and Applied Conditions, ed. McCarty, D.J. & Koopman, W.J., Vol. 1, pp. 279-333. London: Lea & Febiger.
24. QU, Z., LIEBLER, J.M., POWERS, M.R., GALEY, T., AHMADI, P., HUANG, X.N., ANSEL, J.C., BUTTERFIELD, J.H., PLANCK, S.R. & ROSENBAUM, J.Y. (1995). Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am. J. Pathol., 147, 564-573.
25. RAY, J.M. & STETLER-STEVENSON, W.G. (1946). Matrix metalloproteinases and malignant disease: recent developments. Exp. Opin. Invest. Drugs, 5, 323-335.
26. RIZZO, V. & DEFOUW, D.O. (1996). Mast cell activation accelerates the normal rate of angiogenesis in the chick chorioallantoic membrane. Microvasc. Res., 52, 245-257.
27. SEED, M.P. (1996). Angiogenesis inhibition as a drug target for disease: an update. Exp. Opin. Invest. Drugs, 5, 1617-1637.
28. STETLER-STEVENSON, W.G., HEWITT, R. & CORCORAN, M. (1996). Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin. Cancer Biol., 7, 147-154.
29. SUZAWA, H., KIKUCHI, S., ARAI, N. & KODA, A. (1992). The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J. Pharmacol., 60, 91-96.
30. TANAKA, K., HONDA, M., KURAMOCHI, T. & MORIOKA, S. (1994). Prominent inhibitory effects of tranilast on migration and proliferation of and collagen synthesis by vascular smooth muscle cells. Atherosclerosis, 107, 179-185.
31. VUKANOVIC, J., PASSANITI, A., HIRATA, T., TRAYSTMAN, R.J., HARTLEY-ASP, B. & ISAACS, J.T. (1993). Antiangiogenic effects of the quinoline-3-carboxamide linomide. Cancer Res., 53, 1833-1837.
32. YANAGI, T., WATANABE, M., FUKUDA, S. & TSUJI, Y. (1987). Suppressive effects of tranilast (TN) on human mononuclear cells. Jpn J. Inflam. 7, 169-173.